Jeffery W Kelly

List of Publications by Year
in descending order

162	19,064	16791 66	14012 133
papers	citations	h-index	g-index

170	170	170	15265
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Small molecule protein binding to correct cellular folding or stabilize the native state against misfolding and aggregation. Current Opinion in Structural Biology, 2022, 72, 267-278.	2.6	21
2	Amyloidogenic immunoglobulin light chain kinetic stabilizers comprising a simple urea linker module reveal a novel binding sub-site. Bioorganic and Medicinal Chemistry Letters, 2022, 60, 128571.	1.0	5
3	Inverse Drug Discovery identifies weak electrophiles affording protein conjugates. Current Opinion in Chemical Biology, 2022, 67, 102113.	2.8	10
4	Pharmacological activation of ATF6 remodels the proteostasis network to rescue pathogenic GABAA receptors. Cell and Bioscience, 2022, 12, 48.	2.1	14
5	ATF6 Activation Reduces Amyloidogenic Transthyretin Secretion through Increased Interactions with Endoplasmic Reticulum Proteostasis Factors. Cells, 2022, 11, 1661.	1.8	4
6	Response. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 140-141.	1.4	1
7	Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 24-29.	1.4	22
8	Does protein aggregation drive postmitotic tissue degeneration?. Science Translational Medicine, 2021, 13, .	5.8	12
9	Pharmacologic targeting of plasma cell endoplasmic reticulum proteostasis to reduce amyloidogenic light chain secretion. Blood Advances, 2021, 5, 1037-1049.	2.5	19
10	A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	15
11	Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story. Drug Design, Development and Therapy, 2021, Volume 15, 1225-1243.	2.0	29
12	Stereoelectronic effects in stabilizing proteinâ€“N-glycan interactions revealed by experiment and machine learning. Nature Chemistry, 2021, 13, 480-487.	6.6	13
13	Discovery of Potent Coumarin-Based Kinetic Stabilizers of Amyloidogenic Immunoglobulin Light Chains Using Structure-Based Design. Journal of Medicinal Chemistry, 2021, 64, 6273-6299.	2.9	16
14	ATF6 is essential for human cone photoreceptor development. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	31
15	From uncovering the mechanism of transthyretin aggregation to the drug tafamidis for ameliorating neurodegeneration and cardiomyopathy. , 2021, , 65-103.		1
16	Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis. Hemato, 2021, 2, 645-659.	0.2	9
17	Metabolically Activated Proteostasis Regulators Protect against Glutamate Toxicity by Activating NRF2. ACS Chemical Biology, 2021, 16, 2852-2863.	1.6	16
18	Pharmacologic Approaches for Adapting Proteostasis in the Secretory Pathway to Ameliorate Protein Conformational Diseases. Cold Spring Harbor Perspectives in Biology, 2020, 12, a034108.	2.3	25

#	Article	IF	Citations
19	Structure-based design and analysis of SuFEx chemical probes. RSC Medicinal Chemistry, 2020, 11, 10-17.	1.7	83
20	Pharmacologic IRE1/XBP1s activation confers targeted ER proteostasis reprogramming. Nature Chemical Biology, 2020, 16, 1052-1061.	3.9	90
21	Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery. Nature Chemistry, 2020, 12, 906-913.	6.6	85
22	Disruption of the CD Loop by Enzymatic Cleavage Promotes the Formation of Toxic Transthyretin Oligomers through a Common Transthyretin Misfolding Pathway. Biochemistry, 2020, 59, 2319-2327.	1.2	19
23	Brain Permeable Tafamidis Amide Analogs for Stabilizing TTR and Reducing APP Cleavage. ACS Medicinal Chemistry Letters, 2020, 11, 1973-1979.	1.3	12
24	Structural basis for the stabilization of amyloidogenic immunoglobulin light chains by hydantoins. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127356.	1.0	15
25	Amplifiers co-translationally enhance CFTR biosynthesis via PCBP1-mediated regulation of CFTR mRNA. Journal of Cystic Fibrosis, 2020, 19, 733-741.	0.3	35
26	Structural Characterization of Cardiac Ex Vivo Transthyretin Amyloid: Insight into the Transthyretin Misfolding Pathway In Vivo. Biochemistry, 2020, 59, 1800-1803.	1.2	9
27	The Role of Protein Thermodynamics and Primary Structure in Fibrillogenesis of Variable Domains from Immunoglobulin Light Chains. Journal of the American Chemical Society, 2019, 141, 13562-13571.	6.6	24
28	A designed protein binding-pocket to control excited-state intramolecular proton transfer fluorescence. Organic and Biomolecular Chemistry, 2019, 17, 1076-1080.	1.5	13
29	Transthyretin Amyloid Cardiomyopathy. Journal of the American College of Cardiology, 2019, 73, 2872-2891.	1.2	573
30	Quantitative Interactome Proteomics Reveals a Molecular Basis for ATF6-Dependent Regulation of a Destabilized Amyloidogenic Protein. Cell Chemical Biology, 2019, 26, 913-925.e4.	2.5	26
31	Stabilization of amyloidogenic immunoglobulin light chains by small molecules. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8360-8369.	3.3	52
32	Role of domain interactions in the aggregation of full-length immunoglobulin light chains. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 854-863.	3.3	45
33	Pharmacologic ATF6 activation confers global protection in widespread disease models by reprograming cellular proteostasis. Nature Communications, 2019, 10, 187.	5.8	140
34	Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight, 2019, 4, .	2.3	53
35	Mechanism of Action of the Cytotoxic Asmarine Alkaloids. ACS Chemical Biology, 2018, 13, 1299-1306.	1.6	5
36	The unfolded protein response regulator ATF6 promotes mesodermal differentiation. Science Signaling, 2018, 11, .	1.6	54

#	Article	IF	Citations
37	â€œInverse Drug Discoveryâ€•Strategy To Identify Proteins That Are Targeted by Latent Electrophiles As Exemplified by Aryl Fluorosulfates. Journal of the American Chemical Society, 2018, 140, 200-210.	6.6	206
38	Mispacking of the Phe87 Side Chain Reduces the Kinetic Stability of Human Transthyretin. Biochemistry, 2018, 57, 6919-6922.	1.2	8
39	Tenosynovial and Cardiac Amyloidosis inÂPatients Undergoing CarpalÂTunnelÂRelease. Journal of the American College of Cardiology, 2018, 72, 2040-2050.	1.2	209
40	Cellular clearance of circulating transthyretin decreases cell-nonautonomous proteotoxicity in Caenorhabditis elegans. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7710-E7719.	3.3	23
41	NMR Measurements Reveal the Structural Basis of Transthyretin Destabilization by Pathogenic Mutations. Biochemistry, 2018, 57, 4421-4430.	1.2	30
42	The two shapes of the Tau protein. ELife, 2018, 7, .	2.8	3
43	Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 120-128.	1.4	33
44	Deducing the presence of proteins and proteoforms in quantitative proteomics. Nature Communications, 2018, 9, 2320.	5.8	23
45	Age-dependent cognitive dysfunction in untreated hereditary transthyretin amyloidosis. Journal of Neurology, 2018, 265, 299-307.	1.8	16
46	Pharmacologic ATF6 activating compounds are metabolically activated to selectively modify endoplasmic reticulum proteins. ELife, 2018, 7, .	2.8	85
47	Adapting the Chemistry and/or Biology of Proteostasis to Ameliorate Protein Aggregation Diseases. FASEB Journal, 2018, 32, 247.2.	0.2	0
48	An ortho-Iminoquinone Compound Reacts with Lysine Inhibiting Aggregation while Remodeling Mature Amyloid Fibrils. ACS Chemical Neuroscience, 2017, 8, 1704-1712.	1.7	14
49	Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3441-3449.	1.0	8
50	Pathogenic Mutations Induce Partial Structural Changes in the Native Î²-Sheet Structure of Transthyretin and Accelerate Aggregation. Biochemistry, 2017, 56, 4808-4818.	1.2	20
51	Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients. Science Translational Medicine, 2017, 9, .	5.8	44
52	Using Cooperatively Folded Peptides To Measure Interaction Energies and Conformational Propensities. Accounts of Chemical Research, 2017, 50, 1875-1882.	7.6	18
53	Residues Comprising the Enhanced Aromatic Sequon Influence Protein N-Glycosylation Efficiency. Journal of the American Chemical Society, 2017, 139, 12947-12955.	6.6	20
54	Amyloid Accumulation Drives Proteome-wide Alterations in Mouse Models of Alzheimerâ€™s Disease-like Pathology. Cell Reports, 2017, 21, 2614-2627.	2.9	56

#	Article	IF	Citations
55	The endoplasmic reticulum <scp>HSP</scp>40 coâ€chaperone <scp>ER</scp>dj3/<scp>DNAJB</scp>11 assembles and functions as a tetramer. EMBO Journal, 2017, 36, 2296-2309.	3.5	38
56	Incomplete Refolding of Antibody Light Chains to Non-Native, Protease-Sensitive Conformations Leads to Aggregation: A Mechanism of Amyloidogenesis in Patients?. Biochemistry, 2017, 56, 6597-6614.	1.2	26
57	Peripheral Blood Cell Gene Expression Diagnostic for Identifying Symptomatic Transthyretin Amyloidosis Patients: Male and Female Specific Signatures. Theranostics, 2016, 6, 1792-1809.	4.6	22
58	Small molecule proteostasis regulators that reprogram the ER to reduce extracellular protein aggregation. ELife, 2016, 5, .	2.8	185
59	Modulating protein quality control. ELife, 2016, 5, .	2.8	12
60	Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue. Journal of the American Chemical Society, 2016, 138, 7353-7364.	6.6	212
61	Stabilizing the C_H2 Domain of an Antibody by Engineering in an Enhanced Aromatic Sequon. ACS Chemical Biology, 2016, 11, 1852-1861.	1.6	40
62	Solid-State NMR Studies Reveal Native-like Î²-Sheet Structures in Transthyretin Amyloid. Biochemistry, 2016, 55, 5272-5278.	1.2	25
63	Endoplasmic Reticulum Proteostasis Influences the Oligomeric State of an Amyloidogenic Protein Secreted from Mammalian Cells. Cell Chemical Biology, 2016, 23, 1282-1293.	2.5	29
64	The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains. Journal of Molecular Biology, 2016, 428, 4280-4297.	2.0	66
65	Synthesis of Sulfotyrosineâ€Containing Peptides by Incorporating Fluorosulfated Tyrosine Using an Fmocâ€Based Solidâ€Phase Strategy. Angewandte Chemie, 2016, 128, 1867-1870.	1.6	17
66	Synthesis of Sulfotyrosineâ€Containing Peptides by Incorporating Fluorosulfated Tyrosine Using an Fmocâ€Based Solidâ€Phase Strategy. Angewandte Chemie - International Edition, 2016, 55, 1835-1838.	7.2	43
67	The Dependence of Carbohydrateâ€“Aromatic Interaction Strengths on the Structure of the Carbohydrate. Journal of the American Chemical Society, 2016, 138, 7636-7648.	6.6	44
68	Structural Changes Associated with Transthyretin Misfolding and Amyloid Formation Revealed by Solution and Solid-State NMR. Biochemistry, 2016, 55, 1941-1944.	1.2	38
69	High-Resolution Mapping of the Folding Transition State of a WW Domain. Journal of Molecular Biology, 2016, 428, 1617-1636.	2.0	20
70	Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurology and Therapy, 2016, 5, 1-25.	1.4	124
71	A current pharmacologic agent versus the promise of next generation therapeutics to ameliorate protein misfolding and/or aggregation diseases. Current Opinion in Chemical Biology, 2016, 32, 10-21.	2.8	19
72	A Fluorogenic Aryl Fluorosulfate for Intraorganellar Transthyretin Imaging in Living Cells and in Caenorhabditis elegans. Journal of the American Chemical Society, 2015, 137, 7404-7414.	6.6	86

#	Article	IF	Citations
73	Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 175-180.	1.4	34
74	Enhanced Aromatic Sequons Increase Oligosaccharyltransferase Glycosylation Efficiency and Glycan Homogeneity. Chemistry and Biology, 2015, 22, 1052-1062.	6.2	36
75	Individual and Collective Contributions of Chaperoning and Degradation to Protein Homeostasis in E.Âcoli. Cell Reports, 2015, 11, 321-333.	2.9	39
76	Fluorescence Turn-On Folding Sensor To Monitor Proteome Stress in Live Cells. Journal of the American Chemical Society, 2015, 137, 11303-11311.	6.6	37
77	Targeting protein aggregation for the treatment of degenerative diseases. Nature Reviews Drug Discovery, 2015, 14, 759-780.	21.5	338
78	Genetic ablation of Nâ€linked glycosylation reveals two key folding pathways for R345W fibulinâ€3, a secreted protein associated with retinal degeneration. FASEB Journal, 2015, 29, 565-575.	0.2	23
79	Unfolded protein responseâ€induced <scp>ER</scp> dj3 secretion links <scp>ER</scp> stress to extracellular proteostasis. EMBO Journal, 2015, 34, 4-19.	3.5	110
80	Immunoprecipitation of Amyloid Fibrils by the Use of an Antibody that Recognizes a Generic Epitope Common to Amyloid Fibrils. PLoS ONE, 2014, 9, e105433.	1.1	11
81	The intrinsic and extrinsic effects of N-linked glycans on glycoproteostasis. Nature Chemical Biology, 2014, 10, 902-910.	3.9	166
82	Unfolded protein response activation reduces secretion and extracellular aggregation of amyloidogenic immunoglobulin light chain. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13046-13051.	3.3	83
83	ERdj3 Is an Endoplasmic Reticulum Degradation Factor for Mutant Glucocerebrosidase Variants Linked to Gaucherâ€™s Disease. Chemistry and Biology, 2014, 21, 967-976.	6.2	63
84	Quantification of Transthyretin Kinetic Stability in Human Plasma Using Subunit Exchange. Biochemistry, 2014, 53, 1993-2006.	1.2	62
85	Chaperonins Resculpt Folding Free Energy Landscapes to Avoid Kinetic Traps and Accelerate Protein Folding. Journal of Molecular Biology, 2014, 426, 2736-2738.	2.0	4
86	Bifunctional coumarin derivatives that inhibit transthyretin amyloidogenesis and serve as fluorescent transthyretin folding sensors. Chemical Communications, 2013, 49, 9188.	2.2	35
87	Stress-Independent Activation of XBP1s and/or ATF6 Reveals Three Functionally Diverse ER Proteostasis Environments. Cell Reports, 2013, 3, 1279-1292.	2.9	436
88	Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. Journal of Neurology, 2013, 260, 2802-2814.	1.8	284
89	Localized Structural Fluctuations Promote Amyloidogenic Conformations in Transthyretin. Journal of Molecular Biology, 2013, 425, 977-988.	2.0	65
90	Structural and Energetic Basis of Carbohydrateâ€“Aromatic Packing Interactions in Proteins. Journal of the American Chemical Society, 2013, 135, 9877-9884.	6.6	85

#	Article	IF	Citations
91	Repurposing Diflunisal for Familial Amyloid Polyneuropathy. JAMA - Journal of the American Medical Association, 2013, 310, 2658.	3.8	551
92	AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9992-9997.	3.3	120
93	Mechanisms of Transthyretin Inhibition of Î²-Amyloid AggregationIn Vitro. Journal of Neuroscience, 2013, 33, 19423-19433.	1.7	118
94	Tafamidis for transthyretin familial amyloid polyneuropathy. Neurology, 2012, 79, 785-792.	1.5	658
95	Hsp104 Gives Clients the Individual Attention They Need. Cell, 2012, 151, 695-697.	13.5	7
96	The Transthyretin Amyloidoses: From Delineating the Molecular Mechanism of Aggregation Linked to Pathology to a Regulatory-Agency-Approved Drug. Journal of Molecular Biology, 2012, 421, 185-203.	2.0	267
97	Nâ€glycosylation of enhanced aromatic sequons to increase glycoprotein stability. Biopolymers, 2012, 98, 195-211.	1.2	58
98	Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9629-9634.	3.3	582
99	Protein Native-State Stabilization by Placing Aromatic Side Chains in N-Glycosylated Reverse Turns. Science, 2011, 331, 571-575.	6.0	157
100	Dissecting the Structure, Thermodynamic Stability, and Aggregation Properties of the A25T Transthyretin (A25T-TTR) Variant Involved in Leptomeningeal Amyloidosis: Identifying Protein Partners That Co-Aggregate during A25T-TTR Fibrillogenesis in Cerebrospinal Fluid. Biochemistry, 2011, 50, 11070-11083.	1.2	31
101	A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin. Bioorganic and Medicinal Chemistry, 2011, 19, 1505-1514.	1.4	31
102	Glycosylation of the enhanced aromatic sequon is similarly stabilizing in three distinct reverse turn contexts. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14127-14132.	3.3	61
103	A Stilbene That Binds Selectively to Transthyretin in Cells and Remains Dark until It Undergoes a Chemoselective Reaction To Create a Bright Blue Fluorescent Conjugate. Journal of the American Chemical Society, 2010, 132, 16043-16051.	6.6	45
104	Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Current Opinion in Structural Biology, 2010, 20, 54-62.	2.6	160
105	Context-Dependent Effects of Asparagine Glycosylation on Pin WW Folding Kinetics and Thermodynamics. Journal of the American Chemical Society, 2010, 132, 15359-15367.	6.6	69
106	Evaluating Î²-turn mimics as Î²-sheet folding nucleators. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 11067-11072.	3.3	97
107	The core trisaccharide of an N-linked glycoprotein intrinsically accelerates folding and enhances stability. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3131-3136.	3.3	206
108	Sequence determinants of thermodynamic stability in a WW domainâ€”An allâ€Î²â€sheet protein. Protein Science, 2009, 18, 1806-1813.	3.1	63

#	Article	IF	Citations
109	Localized thermodynamic coupling between hydrogen bonding and microenvironment polarity substantially stabilizes proteins. Nature Structural and Molecular Biology, 2009, 16, 684-690.	3.6	178
110	Biological and Chemical Approaches to Diseases of Proteostasis Deficiency. Annual Review of Biochemistry, 2009, 78, 959-991.	5.0	1,035
111	Toward quantification of protein backboneâ€“backbone hydrogen bonding energies: An energetic analysis of an amideâ€toâ€ester mutation in an Î±â€helix within a protein. Protein Science, 2008, 17, 1096-1101.	3.1	38
112	Increasing protein stability using a rational approach combining sequence homology and structural alignment: Stabilizing the WW domain. Protein Science, 2008, 10, 1454-1465.	3.1	44
113	Structural Insight into pH-Induced Conformational Changes within the Native Human Transthyretin Tetramer. Journal of Molecular Biology, 2008, 382, 1157-1167.	2.0	70
114	Quantification of the Thermodynamically Linked Quaternary and Tertiary Structural Stabilities of Transthyretin and Its Disease-Associated Variants: The Relationship between Stability and Amyloidosis. Biochemistry, 2008, 47, 6969-6984.	1.2	115
115	Determinants for dephosphorylation of the RNA polymerase II Câ€terminal domain by Scp1. FASEB Journal, 2007, 21, A1032.	0.2	0
116	Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2006, 13, 236-249.	1.4	236
117	Amide-to-E-Olefin versus Amide-to-Ester Backbone H-Bond Perturbations:Â Evaluating the Oâ‹¯O Repulsion for Extracting H-Bond Energies. Journal of the American Chemical Society, 2006, 128, 15948-15949.	6.6	38
118	Determinants for Dephosphorylation of the RNA Polymerase II C-Terminal Domain by Scp1. Molecular Cell, 2006, 24, 759-770.	4.5	103
119	Structure-function-folding relationship in a WW domain. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10648-10653.	3.3	199
120	Therapeutic Strategies Against Gain and Loss of Function Misfolding Diseases. FASEB Journal, 2006, 20, A850.	0.2	0
121	The Pathway by Which the Tetrameric Protein Transthyretin Dissociatesâ€. Biochemistry, 2005, 44, 15525-15533.	1.2	149
122	Backboneâ€“Backbone Hâ€Bonds Make Contextâ€Dependent Contributions to Protein Folding Kinetics and Thermodynamics: Lessons from Amideâ€toâ€Ester Mutations. Advances in Protein Chemistry, 2005, 72, 39-78.	4.4	60
123	Kinetic Stabilization of an Oligomeric Protein under Physiological Conditions Demonstrated by a Lack of Subunit Exchange:â€‰ Implications for Transthyretin Amyloidosis. Biochemistry, 2005, 44, 9265-9274.	1.2	58
124	Attacking Amyloid. New England Journal of Medicine, 2005, 352, 722-723.	13.9	25
125	Kinetic Stabilization of the Native State by Protein Engineering: Implications for Inhibition of Transthyretin Amyloidogenesis. Journal of Molecular Biology, 2005, 347, 841-854.	2.0	73
126	The Biological and Chemical Basis for Tissue-Selective Amyloid Disease. Cell, 2005, 121, 73-85.	13.5	427

#	Article	IF	Citations
127	Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2817-2822.	3.3	336
128	Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Laboratory Investigation, 2004, 84, 545-552.	1.7	186
129	Context-dependent contributions of backbone hydrogen bonding to Î²-sheet folding energetics. Nature, 2004, 430, 101-105.	13.7	260
130	Toward Assessing the Position-Dependent Contributions of Backbone Hydrogen Bonding to Î²-Sheet Folding Thermodynamics Employing Amide-to-Ester Perturbations. Journal of the American Chemical Society, 2004, 126, 16762-16771.	6.6	107
131	Transthyretin Aggregation under Partially Denaturing Conditions Is a Downhill Polymerizationâ€. Biochemistry, 2004, 43, 7365-7381.	1.2	303
132	Benzoxazoles as Transthyretin Amyloid Fibril Inhibitors: Synthesis, Evaluation, and Mechanism of Action. Angewandte Chemie - International Edition, 2003, 42, 2758-2761.	7.2	204
133	Amyloid as a natural product. Journal of Cell Biology, 2003, 161, 461-462.	2.3	109
134	Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics. Science, 2003, 299, 713-716.	6.0	491
135	Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 16427-16432.	3.3	320
136	Synthesis of a Negatively Charged Dibenzofuran-Based Î²-Turn Mimetic and Its Incorporation into the WW Miniprotein-Enhanced Solubility without a Loss of Thermodynamic Stability. Journal of the American Chemical Society, 2002, 124, 11900-11907.	6.6	46
137	Native State Hydrogen Exchange Study of Suppressor and Pathogenic Variants of Transthyretin. Journal of Molecular Biology, 2002, 320, 821-832.	2.0	41
138	NMR solution structure of the isolated Apo Pin1 WW domain: Comparison to the x-ray crystal structures of Pin1. Biopolymers, 2002, 63, 111-121.	1.2	69
139	The folding mechanism of a Î²-sheet: the WW domain. Journal of Molecular Biology, 2001, 311, 373-393.	2.0	297
140	Anion Shielding of Electrostatic Repulsions in Transthyretin Modulates Stability and Amyloidosis:Â Insight into the Chaotrope Unfolding Dichotomyâ€. Biochemistry, 2001, 40, 11453-11459.	1.2	80
141	An Engineered Transthyretin Monomer that Is Nonamyloidogenic, Unless It Is Partially Denaturedâ€. Biochemistry, 2001, 40, 11442-11452.	1.2	219
142	Transthyretin slowly exchanges subunits under physiological conditions: A convenient chromatographic method to study subunit exchange in oligomeric proteins. Protein Science, 2001, 10, 1606-1613.	3.1	99
143	Trans-Suppression of Misfolding in an Amyloid Disease. Science, 2001, 293, 2459-2462.	6.0	282
144	Structure-Based Design, Synthesis and Evaluation of Amyloid Fibril Inhibitors. Biochemical Society Transactions, 2000, 28, A51-A51.	1.6	0

#	Article	IF	Citations
145	A glimpse of a possible amyloidogenic intermediate of transthyretin. Nature Structural Biology, 2000, 7, 754-757.	9.7	121
146	Deuterium-proton exchange on the native wild-type transthyretin tetramer identifies the stable core of the individual subunits and indicates mobility at the subunit interface 1 1Edited by P. E. Wright. Journal of Molecular Biology, 2000, 303, 555-565.	2.0	64
147	Characterization of the Structure and Function of W â†' F WW Domain Variants:Â Identification of a Natively Unfolded Protein That Folds upon Ligand Bindingâ€. Biochemistry, 1999, 38, 14338-14351.	1.2	79
148	The Most Pathogenic Transthyretin Variant, L55P, Forms Amyloid Fibrils under Acidic Conditions and Protofilaments under Physiological Conditionsâ€. Biochemistry, 1999, 38, 13560-13573.	1.2	179
149	WW: An isolated threeâ€stranded antiparallel Î²â€sheet domain that unfolds and refolds reversibly; evidence for a structured hydrophobic cluster in urea and GdnHCl and a disordered thermal unfolded state. Protein Science, 1999, 8, 841-853.	3.1	137
150	The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Current Opinion in Structural Biology, 1998, 8, 101-106.	2.6	992
151	Characterization of the Transthyretin Acid Denaturation Pathways by Analytical Ultracentrifugation:Â Implications for Wild-Type, V30M, and L55P Amyloid Fibril Formationâ€. Biochemistry, 1998, 37, 17851-17864.	1.2	207
152	Comparative Characterization of a Wild Type and Transmembrane Domain-Deleted Fatty Acid Amide Hydrolase:â€‰ Identification of the Transmembrane Domain as a Site for Oligomerization. Biochemistry, 1998, 37, 15177-15187.	1.2	149
153	Guanidine Hydrochloride-Induced Denaturation and Refolding of Transthyretin Exhibits a Marked Hysteresis:Â Equilibria with High Kinetic Barriersâ€. Biochemistry, 1997, 36, 10230-10239.	1.2	101
154	Improving mass spectrometric sequencing of arginine-containing peptides by derivatization with acetylacetone. , 1997, 32, 1337-1349.		38
155	The Acid-Mediated Denaturation Pathway of Transthyretin Yields a Conformational Intermediate That Can Self-Assemble into Amyloidâ€. Biochemistry, 1996, 35, 6470-6482.	1.2	547
156	Nucleated Antiparallel Î²-Sheet That Folds and Undergoes Self-Assembly:Â A Template Promoted Folding Strategy toward Controlled Molecular Architectures. Macromolecules, 1996, 29, 355-366.	2.2	63
157	Alternative conformations of amyloidogenic proteins govern their behavior. Current Opinion in Structural Biology, 1996, 6, 11-17.	2.6	601
158	Examining the structural and functional roles of the ?-turn region in neuropeptide Y. International Journal of Peptide Research and Therapeutics, 1996, 3, 133-142.	0.1	0
159	A chemical approach to elucidate tin mechanism of transthyretin and Î²-protein amyloid fibril formation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1994, 1, 186-205.	1.4	108
160	Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry, 1993, 32, 12119-12127.	1.2	200
161	Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry, 1992, 31, 8654-8660.	1.2	521
162	Proteostasis Modulation Prevents Photoreceptor Pathology in Retinal Organoids. SSRN Electronic Journal, 0, , .	0.4	1